IDEAYA Biosciences (IDYA) reported a Q1 net loss Tuesday of $0.82 per diluted share.
Analysts polled by FactSet expected a loss of $0.66.
As expected, no revenue for the quarter ended March 31 was reported.
As of March 31, the company said it had $1.05 billion in cash and/or cash equivalents on hand, and expects it could be sufficient to fund operations through 2029.
The company's shares were up 1.7% in recent premarket activity on Tuesday.
Price: 20.83, Change: +0.36, Percent Change: +1.73
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.